Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors
Details
Serval ID
serval:BIB_7186771F86B7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors
Journal
International Journal of Cancer
ISSN
0020-7136 (Print)
Publication state
Published
Issued date
11/1995
Volume
63
Number
5
Pages
665-72
Notes
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Nov 27
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Nov 27
Abstract
The matrix protein tenascin-C (TN-C) is present in the blood of healthy individuals at concentrations around 1 mg/l. Elevated serum levels have been reported in cancer patients. In this study we have measured the concentration of circulating TN-C in 40 patients with melanoma, soft-tissue sarcoma (STS) or squamous-cell carcinoma (SCC) of the limbs, and have found a minor increase in the mean concentration compared with healthy subjects. Only 10 patients had TN-C levels above the normal range. No correlation was observed between TN-C levels and tumor burden. Nineteen patients were treated by isolation limb perfusion (ILP) with TNF, IFN gamma, melphalan (11 melanoma, 2 SCC and I STS), melphalan alone (3 melanoma) or hyperthermia at 41.5 degrees C (2 melanoma). ILP with TNF, IFN gamma and melphalan induced a rapid increase in plasma TN-C levels, peaking in most patients between 24 or 48 hr after ILP. Two patients treated with hyperthermia only had a slow increase in TN-C concentration peaking at day 4, while the patients treated with melphalan alone had no significant change. In some cases elevated TN-C levels persisted for over 8 weeks after ILP. The early rise in TN-C concentration correlates with the increase in circulating C-reactive protein. Our findings suggest that circulating TN-C behaves, at least in part, as an acute-phase protein and that it may play a role in the inflammatory response.
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/*administration &
dosage/adverse effects
Blood Platelets/drug effects
C-Reactive Protein/metabolism
Carcinoma, Squamous Cell/blood/drug therapy
Chemotherapy, Cancer, Regional Perfusion
Dose-Response Relationship, Drug
*Extremities
Female
Humans
Interferon-gamma, Recombinant/administration & dosage
Interleukin-6/blood
Liver Diseases/chemically induced
Male
Melanoma/blood/drug therapy/secondary
Melphalan/administration & dosage
Middle Aged
Neoplasms/*blood/*drug therapy
Sarcoma/blood/drug therapy
Soft Tissue Neoplasms/blood/drug therapy
Tenascin/*blood
Tumor Necrosis Factor-alpha/administration & dosage/metabolism
Pubmed
Create date
28/01/2008 9:36
Last modification date
20/08/2019 15:30